Clinician Scientist
Dr. med. Julian Lohmeyer
Department of Internal Medicine II, Hematology/ Oncology
Research Focus: Cellular Therapies, Cancer Immunology, Tumor Microenvironment, mRNA-based Immunotherapies, Targeted Drug Delivery, Gene Delivery Systems
Contact: lohmeyer@med.uni-frankfurt.de
Member of the Oellerich Lab
The therapeutic success of CAR-T cells in cancer treatment is limited by primary therapy resistance and relapses after an initial response. To gain a better understanding of therapy resistance at the cellular and molecular levels within the tumor microenvironment, the Oellerich lab employs state-of-the-art gene and protein multi-omic analyses. mRNA coding for proteins capable of modulating the tumor microenvironment will be used as a tumor therapy in mouse models and can be combined with established immunotherapies, such as CAR-T cell therapy. For in vivo administration, the research group utilizes the innovative gene delivery technology known as “Charge-Altering Releasable Transporters”. Looking ahead, this work aims to contribute to a deeper understanding of resistance mechanisms to immunotherapies and may provide a preclinical rationale for the use of mRNA-based immunotherapy as an adjuvant to CAR-T cell therapy.
Find out more about the Oellerich Lab here.
